Rani Therapeutics Holdings Inc (RANI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rani Therapeutics Holdings Inc (RANI) has a cash flow conversion efficiency ratio of 0.423x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.06 Million) by net assets ($-11.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Rani Therapeutics Holdings Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Rani Therapeutics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Rani Therapeutics Holdings Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Rani Therapeutics Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rani Therapeutics Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Galleon Gold Corp
V:GGO
|
-0.019x |
|
Jinro Distillers Co. Ltd
KQ:018120
|
0.107x |
|
Chips&Media Inc
KQ:094360
|
0.065x |
|
CANBRIDGE PHARM.DL-00001
F:MF1
|
N/A |
|
Aniplus Inc
KQ:310200
|
0.106x |
|
Lakeshore Acquisition III Corp. Ordinary Shares
NASDAQ:LCCC
|
-0.001x |
|
Apontis Pharma AG
XETRA:APPH
|
-0.061x |
|
Summit State Bank
NASDAQ:SSBI
|
0.071x |
Annual Cash Flow Conversion Efficiency for Rani Therapeutics Holdings Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Rani Therapeutics Holdings Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see RANI market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $3.49 Million | $-35.50 Million | -10.162x | -404.63% |
| 2023-12-31 | $25.44 Million | $-51.24 Million | -2.014x | -220.38% |
| 2022-12-31 | $74.00 Million | $-46.52 Million | -0.629x | -136.97% |
| 2021-12-31 | $121.57 Million | $-32.24 Million | -0.265x | -300.95% |
| 2020-12-31 | $-113.34 Million | $-14.96 Million | 0.132x | -51.44% |
| 2019-12-31 | $-96.64 Million | $-26.27 Million | 0.272x | -- |
About Rani Therapeutics Holdings Inc
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug subst… Read more